Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

Ab­b­Vie and San­doz have re­solved their patent dis­pute over Ab­b­Vie’s block­buster im­munol­o­gy drug Rin­voq. San­doz ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...

The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...